Capstone Therapeutics Corporation has received a deficiency letter from the Nasdaq Listing Qualifications Department after its common stock closed below the minimum required bid price of $1.00 per share for 30 consecutive business days. This notice, issued under Nasdaq Listing Rule 5550(a)(2), does not immediately affect the company's listing. Capstone has until July 6, 2026, to regain compliance by achieving a closing bid price of $1.00 or more for at least 10 consecutive business days. If compliance is not regained within this period, the company may be eligible for an additional 180-day extension, provided it meets other listing standards. Failure to comply could result in the company's securities being delisted from the Nasdaq Capital Market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-003008), on January 09, 2026, and is solely responsible for the information contained therein.